Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Proof of Concept, Open-label, Forced Titration, Multi-center Study to Assess the Safety/Tolerability and Efficacy of 10-weeks Treatment of LCI699 Followed by a 12 - Week Treatment Period of LCI699 in Patients With Cushing's Disease

Trial Profile

A Proof of Concept, Open-label, Forced Titration, Multi-center Study to Assess the Safety/Tolerability and Efficacy of 10-weeks Treatment of LCI699 Followed by a 12 - Week Treatment Period of LCI699 in Patients With Cushing's Disease

Status: Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 03 Sep 2019

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Osilodrostat (Primary)
  • Indications Pituitary ACTH hypersecretion
  • Focus Proof of concept; Therapeutic Use
  • Acronyms LINC-1; LINC-2
  • Sponsors Novartis
  • Most Recent Events

    • 23 Aug 2019 Planned End Date changed from 21 Dec 2018 to 11 Nov 2019.
    • 23 Aug 2019 Planned primary completion date changed from 21 Dec 2018 to 11 Nov 2019.
    • 04 Apr 2017 Results from an Extension to the Linc-2 Study (n=16) presented at The 99th Annual Meeting of the Endocrine Society
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top